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Tat of HIV-2 (Tat-2) requires host cellular factors for optimal function. We show that transactivation by Tat-2 of the HIV
promoter requires cis-acting binding sites for Sp1 or Sp1 brought to the promoter via a heterologous system. We demonstrate
that an activation domain in Tat-2 consists of one of two potential a-helices in the amino-terminal region, the cysteine-rich
region, and the core region and that this independent activation domain requires cis-acting Sp1-binding sites for function.
Tat-2 interacts with Sp1 in in vitro binding assays, and these interactions require basic residues outside of the Tat-2
activation domain. The regions in Sp1 sufficient for functional synergy with Tat are the Sp1 activation domains, while the
DNA-binding region is dispensable. Substitution mutations of a glutamine-rich region in one Sp1 activation domain, which
eliminate interactions with a TBP-associated factor, also significantly decrease synergy with Tat. Thus, the functional synergy
between Tat-2 and Sp1 localizes to domains in each activator that interact with components of the transcription complex.
We suggest that these interactions, rather than direct Tat/Sp1 binding, result in highly processive RNA polymerase II
complexes and full-length viral transcripts. q 1997 Academic Press
INTRODUCTION pendent functions (Selby and Peterlin, 1990; Southgate
and Green, 1991). A basic region is necessary and suffi-
Human immunodeficiency virus type 2 (HIV-2) is a caus-
cient to bind to TAR-1 (Hauber et al., 1989; Weeks et
ative agent for AIDS. In contrast to HIV-1, HIV-2 is associ-
al., 1990). An activation domain consists of the amino-
ated with a longer asymptomatic period and with lower
terminal, cysteine-rich, and core regions of Tat-1 andrates of heterosexual and perinatal transmission than
provides interactions with the transcription machinerythose of HIV-1 (Kanki et al., 1994; Marlink et al., 1994;
(Derse et al., 1991; Selby and Peterlin, 1990; SouthgatePoulsen et al., 1992). Both lentiviruses absolutely require
and Green, 1991). Tat-2 consists of 130 residues andviral regulatory proteins for high-level viral replication, one
also possesses modular function. A TAR-binding domainof which is the transactivator, Tat (reviewed in Cullen,
is found in a basic region in exon 1 of Tat-2 and requires1993; Jones and Peterlin, 1994). Tat of HIV-1 (Tat-1) and
the second exon for optimal binding (Chang and Jeang,of HIV-2 (Tat-2) greatly increases viral transcription from
1992; Rhim and Rice, 1994; Pagtakhan and Tong-the respective HIV promoter regions, or long terminal re-
Starksen, 1995). An independent activation domain in-peats (LTRs). Tat is brought to the promoter through bind-
cludes the amino-terminal, cysteine-rich, and core re-ing with the nascent viral RNA species, TAR, which is
gions of Tat-2 (Rhim and Rice, 1994; Pagtakhan andtranscribed from the LTRs (reviewed in Jones and Peterlin,
Tong-Starksen, 1995). While the latter two regions have1994). Tat interacts with the transcription machinery to
greater than 65% amino acid sequence homology withconvert nonprocessive RNA polymerase II complexes,
the corresponding regions of Tat-1, the amino-terminalwhich produce short RNA transcripts, to processive forms
region has only 10% homology (Myers et al., 1989). Ex-that produce full-length viral transcripts (reviewed in Cul-
change of the amino-terminal regions in the context oflen, 1993; Jones and Peterlin, 1994).
exon 1 of Tat-1 or exon 1 of Tat-2 results in significantlyTat-1 consists of 86 residues encoded by two exons
decreased transactivation (Echetebu and Rice, 1993).(Myers et al., 1989). Exon 1 encodes a protein of 72
One possible function of the activation domain is inter-residues that efficiently transactivates the HIV-1 pro-
action with the host transcriptional complex. In supportmoter in vitro (Kuppuswamy et al., 1989; Muesing et al.,
of this model, Tat-1 can bind components of the RNA1987), while exon 2 is required for viral replication and
polymerase II complex, such as the holoenzyme complexeffects of Tat-1 on non-HIV promoters (Howcroft et al.,
(Cujec et al., 1997), TATA-binding protein (TBP) in TFIID1995; Neuvent and Jeang, 1996). Exon 1 of Tat-1 displays
(Kashanchi et al., 1994), TBP-associated factor (TAF) 55modular function with discrete domains involved in inde-
(Chiang and Roeder, 1995), TFIIE, TFIIF, and TFIIH (Pa-
rada and Roeder, 1996). Although binding to general tran-1 To whom reprint requests should be addressed at current address:
scription factors is necessary for transactivation by Tat-Roche Bioscience, 3401 Hillview Avenue, Palo Alto, CA 94304. E-mail:
sandra.tong@roche.com. 1, maximal effects require interactions with additional
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cellular cofactors. Tat-binding cofactors include Tat-as- the three binding sites for Sp1 from the HIV-1 LTR in-
serted at position 043 in p(043)CAT (Jeang et al., 1993).sociated kinase (TAK) (Herrmann and Rice, 1995), Tat-
SF1 (Zhou and Sharp, 1996), and transcription factor Sp1 As previously described, the target plasmids pG1(031)-
HIVLTR and pG5(031)HIVLTR are synthetic promoters(Jeang et al., 1993; Kamine and Chinnadurai, 1992). In
in vitro assays, TAK hyperphosphorylates the carboxyl- containing one and five copies, respectively, of the GAL4
DNA-responsive element (upstream activating se-terminal domain of RNA polymerase II, which is required
for transition from initiation to elongation by the transcrip- quences, UAS) upstream of a minimal HIV-1 LTR, posi-
tions 031 to /84, containing the complete TAR;tion complex (Herrmann and Rice, 1995). Tat-SF1 is re-
quired for Tat-1 activity in in vitro transcription assays, pG6(0119)DTAR, pG6(083)DTAR, and pG6(031)DTAR
contain six copies of UAS upstream of the indicated posi-enhances Tat-1 activity in transfection assays, and is the
substrate for a cellular kinase in the presence of TAR-1 tions in an HIV-1 LTR lacking TAR sequences down-
stream of postion 25 (kind gifts from M. Green; Southgate(Zhou and Sharp, 1996). Sp1 is also required for Tat-1
activity in in vitro transcription assays (Sune and Garcia- and Green, 1991). All target plasmids contain the CAT
reporter gene. pHIV2CAT contains the entire HIV-2 LTRBlanco, 1995; Zhou and Sharp, 1995). Interaction be-
tween Sp1 and Tat-1 has been demonstrated in HIV-1- sequences upstream of the CAT reporter gene and has
been previously described (Tong-Starksen et al., 1993).infected cells (Jeang et al., 1993).
In addition to binding with transcription factors, Tat-1 The effector plasmids pRSVTAT2 and pRSVTAT2(1–
99) contain the Rous sarcoma virus (RSV) LTR upstreamdisplays different levels of functional synergy with differ-
ent classes of transcription factors. Synergy with factors of the complete tat-2 cDNA and exon 1 of tat-2, respec-
tively, as previously described (Tong-Starksen et al.,that increase both initiation and elongation (designated
type IIB), such as herpes simplex virus protein VP16, is 1993). The expression vectors encoding the GAL4 DNA-
binding domain (residues 1–147; pSG424 in Sadowskimuch less efficient than with factors that increase only
transcription initiation (designated type I) (Blau et al., and Ptashne, 1989) fused to the complete tat-2 cDNA
and exon 1 of tat-2 in pGAL4cTAT2 and pGAL4TAT2(1–1996). Synergy with the prototypic type I factor, Sp1, is
demonstrated in in vitro transcription systems (Sune and 99), respectively, have been previously described (Pag-
takhan and Tong-Starksen, 1995). pGAL4TAT2(1–80),Garcia-Blanco, 1995) and by the requirement for Sp1-
binding sites in efficient transactivation by Tat-1 with the pGAL4TAT2(18–130), and pGAL4TAT2(46–130) were
constructed by PCR amplification of tat-2 cDNA encodingnative HIV-1 promoter (Jeang et al., 1993; Kamine and
Chinnadurai, 1992), the HIV-2 promoter (Blau et al., 1996), the indicated amino acids followed by directional sub-
cloning into XmaI–XbaI sites in pSG424. pGAL4-and synthetic promoters (Kamine et al., 1991; Southgate
and Green, 1991). The mechanisms for Sp1-dependent TAT2(D26–45) contains tat-2 cDNA encoding Tat-2 with
an internal deletion of residues 26 to 45, inclusive. pGAL-Tat-1 function are not clearly understood and Sp1 depen-
dence for Tat-2 has not been demonstrated. 4TAT2(R81–84A) and pGAL4TAT2(K70A) contain full-
length tat-2 cDNA encoding the indicated substitutionHere we show that optimal transactivation by Tat-2
requires binding sites for Sp1 or Sp1 brought to the pro- mutations. Inserts for these three plasmids were con-
structed by recombinant PCR and insertion into XmaI –moter by a heterologous system. We define the activation
domain of Tat-2 in detail and demonstrate a requirement XbaI sites in pSG424. Each plasmid construction was
confirmed by sequencing by dye-terminator cycle-se-for Sp1 binding sites for the activation function of Tat-2.
We define the residues in Tat-2 required for binding to quencing to ensure that inserts were in-frame with GAL4
sequences and encoded the correct Tat-2 residues.Sp1 in in vitro binding assays; these residues map out-
side of the activation domain of Tat-2. Finally, we show The expression vector encoding the GAL4 DNA-binding
domain (residues 1–147) fused to the activation domain ofthat Sp1 activation domains, including residues that con-
tact a TBP-associated factor, are necessary and suffi- VP16 (residues 413–490, pGAL4-VP16 in Southgate and
Green, 1991) and E1A (residues 121–223, pGAL4-E1a incient for functional interactions with Tat-2. These data
suggest a model in which functional synergy between Southgate and Green, 1991) have been previously de-
scribed. The expression vector encoding the GAL4 DNA-Tat-2 and Sp1 requires contacts between the transcrip-
tion complex and the activation domain of each factor binding domain fused to full-length human Sp1 (residues
83–778; pGAL4-SP1WT in Emami et al., 1995) or domainsrather than direct Tat-2/Sp1 binding.
from Sp1 have been previously described (kind gifts from G.
Gill). In brief, pGAL4SP1A/B expresses the GAL4-bindingMATERIALS AND METHODS
domain fused to residues 83 to 621 of Sp1 cDNA (Emami et
Plasmid constructions
al., 1995). pGAL4SP1A expresses the GAL4-binding domain
fused to residues 83 to 262 (Emami et al., 1995; kind giftThe target plasmid p(043)CAT contains the HIV-1 LTR
from position 043 to /78 upstream of the chlorampheni- from S. Smale). pGAL4SP1B expresses the GAL4-binding
domain fused to residues 263–542 (Gill et al., 1994).col acetyl transferase, or CAT, reporter gene as pre-
viously described (Jeang et al., 1993). pSp1CAT contains pGAL4SP1DBD expresses the GAL4-binding domain fused
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to residues 612 to 778 (kind gift from M. Green; Liu and Escherichia coli strain B21 were transformed with each
GST-Tat2 plasmid.Green, 1994). pGAL4SP1B-n expresses the GAL4-binding
domain fused to residues 263–424 (Gill et al., 1994). E. coli lysates were generated using published proto-
cols as described by the NIH AIDS Research and Refer-pGAL4SP1B-c expresses the GAL4-binding domain fused
to residues 421–542 (Gill et al., 1994). pGAL4SP1(m455– ence Reagent Program (Rhim et al., 1994). Lysates from
transformed E. coli were equilibrated with 45 ml of gluta-466) expresses the GAL4-binding domain fused to residues
421–542 containing substitution mutations GAAGIRWKIP- thione–Sepharose beads in a 50% slurry with EBC-DTT
buffer (50 mM Tris–HCl, pH 8, 120 mM NaCl, 0.5% NP-at residues 455 to 465 (called pGAL4SP1 B-c M37 in Gill
et al., 1994). pGAL4SP1(W–A), pGAL4SP1(L–A), and 40, 5 mM DTT, 2 mg/ml aprotinin, 1 mg/ml leupeptin,
50 mg/ml phenylmethylsulfonyl fluoride). During the lastpGAL4SP1(Q–A) express the GAL4-binding domain fused
to region B-c with the following substitution mutations, re- wash with EBC-DTT buffer, an aliquot of 1/10 bound pro-
tein and beads was removed, eluated by boiling, andspectively: W457A; L460,462,465A; Q461,463,464A (Gill et
al., 1994). analyzed on a 12% SDS–polyacrylamide gel (PAGE) fol-
lowed by Coomassie blue staining to quantitate fusion
Transient transfection assays protein expression. HeLa whole-cell extracts (WCE) were
prepared from 50–75 1 106 cells/per sample lysed with
For each assay, 2 1 106 HeLa cells were transfected
1 ml RIPA buffer (150 mM NaCl, 50 mM Tris, pH 8, 1%
as previously described using DEAE-dextran (Jeang et
NP-40, 0.5% deoxycholate, 0.1% SDS, 2 mg/ml aprotinin, 1
al., 1993). One microgram of target plasmid and 1 mg of
mg/ml leupeptin, 50 mg/ml phenylmethylsulfonyl fluoride).
effector plasmid were used in all transfections unless
WCE were precleared with 45 ml of glutathione–Sepha-
otherwise stated. CAT assays were performed as pre-
rose beads in a 50% slurry. In vitro binding was per-
viously described by measurement of acetylation of [14C]-
formed by incubation of 1 ml of HeLa WCE with GST
chloramphenicol using thin-layer chromatography (Tong-
alone or GST–Tat2 fusions bound to glutathione–Sepha-
Starksen et al., 1993). An internal control consisted of 2
rose beads for 1 h at 47. Bound complexes and beads
mg of an independent reporter construction containing
were pelleted and washed three times with wash buffer
the b-actin promoter upstream of the human chorionic
(150 mM NaCl, 20 mM HEPES, 0.1% NP-40, and 10%
gonadtropin (HCG) gene (Tong-Starksen et al., 1993).
glycerol). The complexes were eluted and resolved by
HCG concentrations were measured with the Tandem-R
electrophoresis on 8% SDS–PAGE.
HCG Assay kit (Hybridtech, Inc., San Diego, CA; discon-
Electrophoresed proteins were subsequently trans-
tinued product). A second internal control was quantita-
ferred to nitrocellulose membrane and soaked in TBS
tion of protein concentration in lysates of transfected
blocking buffer (150 mM NaCl, 10 mM Tris, pH 8, 0.05%
cells (Tong-Starksen et al., 1987). CAT activities were
Tween 20, and 5% milk). As directed by the manufacturer
normalized to constant amounts of secreted HCG or to
of the primary antibody (Santa Cruz Biotech, Inc., Santa
10 mg of protein in cell lysates. Experimental data normal-
Cruz, CA), membranes were incubated with anti-hSp1
ized to both of these internal controls did not have statisti-
rabbit polyclonal sera at 0.75 mg/ml final concentration,
cally significant differences so that protein concentra-
washed, and incubated for 30–45 min with anti-rabbit
tions were used after discontinuation of the Tandem-R
secondary antibody (1:5000) conjugated with horseradish
HCG Assay kit. Data shown are the means of at least
peroxidase. After three washes in TBS, the presence of
three independent transfections.
transcription factor Sp1 was detected using the Amer-
sham ECL Western blotting analysis system (ArlingtonIn vitro binding assays
Heights, IL).
The following reagent was obtained through the AIDS
Research and Reference Reagent Program, Division of RESULTS
AIDS, NIAID, NIH: BL21 bacteria transformed with pGST-
Requirement for Sp1 in transactivation by Tat-2
Tat 2 130R from Dr. Andrew Rice (Rhim et al., 1994).
pGST-Tat2 130R expresses full-length Tat-2 (residues 1 – To demonstrate the functional dependence of Tat-2
on Sp1, we tested transactivation of a minimal HIV-1130) fused to glutathione S-transferase (GST). pGST-
Tat2(46–130) and pGST-Tat2(1–80) were constructed by promoter in the absence and presence of binding sites
for Sp1. p(043)CAT, which contains a TATA box andPCR amplification of tat-2 cDNA encoding the indicated
residues. pGST-Tat2(R81–84A) was constructed using TAR in a minimal HIV-1 LTR, and pSp1CAT, which con-
tains three Sp1-binding sites upstream of the minimalrecombinant PCR to generate tat-2 encoding the substi-
tution mutations of R81 –84 with alanine residues in the HIV-1 LTR, were transiently transfected into HeLa cells
in the absence or presence of Tat-2(1 – 130) expressedcontext of full-length cDNA. PCR inserts encoding mu-
tated Tat-2 were directionally subcloned into BamHI and by the RSV LTR (pRSVTAT2) (Tong-Starksen et al., 1993).
Transactivation of p(043)CAT was not observed withEcoRI sites in pGST-Tat2 130R to replace wild-type tat-2
and were confirmed by dye-terminator cycle-sequencing. pRSVTAT2 (Fig. 1). In agreement with previous work,
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FIG. 1. Transactivation by Tat-2 requires binding sites for Sp1. Target plasmids contained a minimal HIV-1 promoter (sequences 043 to /78)
without [p(043)CAT] or with (pSp1CAT) three copies of binding sites for Sp1 upstream of the CAT reporter gene (Jeang et al., 1993). Effector plasmids
expressed full-length Tat-2 (pRSVTAT2) or exon 1 of Tat-2 [pRSVTAT2(1–99)] downstream of the RSV LTR (Tong-Starksen et al., 1993). 3 mg of
effector and target plasmids were used in each experiment. Basal activity shown was the CAT activity of each target plasmid with pUC9. The graph
shows the average fold transactivations and SEM from at least three independent transfections.
we find that Sp1-binding sites in pSp1CAT resulted in without Tat-2 was 6-fold (Fig. 2). Transactivation by
pGAL4-SP1WT and pRSVTat-2 was 198-fold, which wasbasal activity that was 9-fold higher than that of
p(043)CAT in the absence of any transactivators (Fig. 32-fold over the effect of pGAL4-SP1WT alone.
To determine whether Tat-2 could synergize with other1) (Jeang et al., 1993). Cotransfection of pSp1CAT with
pRSVTAT-2 resulted in 118-fold transactivation over classes of transcription factors, we examined the effect
of activation domains from other transactivators, E1Abasal activity (Fig. 1). To determine whether deletion of
exon 2 of Tat-2 affected the requirement for Sp1-binding from adenovirus and VP16 from the herpes simplex virus,
fused to the GAL4-binding domain (pGAL4-VP16 andsites, we cotransfected pRSVTAT2(1 – 99), which consti-
tutively expresses exon 1 of Tat-2, with p(043)CAT or pGAL4-E1a; Southgate and Green, 1991). Each of these
hybrid transactivators resulted in significant transactiva-pSp1CAT. Transactivation of p(043)CAT was not ob-
served but transactivation of pSp1CAT was 53-fold (Fig. tion in the absence of Tat-2, 276-fold for pGAL4-E1a and
38-fold for pGAL4-VP16 (Fig. 2). The addition of1). Decreased transactivation by Tat-2(1 – 99) is in agree-
ment with previous work that shows decreased binding pRSVTAT2 resulted in only 1.4- and 3.8-fold additional
transactivation, respectively (Fig. 2). Thus, maximal syn-to TAR-1 in the absence of exon 2 of Tat-2 (Rhim and
Rice, 1994; Pagtakhan and Tong-Starksen, 1995). Thus, ergy is observed between pGAL4-SP1WT and pRSVTAT2.
binding sites for Sp1 are required for Tat-2 transactiva-
Definition of activation domain of Tat-2tion, and this requirement is not affected by decreased
TAR-binding function of Tat-2. To define the mechanism for functional interactions
It is possible that cellular factors other than Sp1 bind between Tat-2 and Sp1, we first defined functional do-
to the three GC-rich sites in the HIV-1 LTR. To demon- mains within Tat-2 in detail. We defined the independent
strate that transcription factor Sp1 was specifically re- activation domain of Tat-2 using a heterologous DNA-
quired for optimal transactivation by Tat-2, we used binding system. The target was the synthetic promoter–
Sp1(83–778) fused to the heterologous DNA-binding do- reporter construction, pG6(0119)DTAR, which contains
main from GAL4 protein (pGAL4-SP1WT) (Emami et al., six copies of UAS upstream of position 0119 of the HIV-
1995) in transient transfection assays in HeLa cells. 1 LTR lacking TAR (Southgate and Green, 1991). The
Transactivation by pGAL4-SP1WT was tested on a syn- effectors express wild-type or mutated Tat-2 fused down-
thetic promoter–reporter containing one copy of the stream of the GAL4 DNA-binding domain. Transient co-
GAL4 DNA-binding site (UAS) upstream of a minimal HIV- transfections in HeLa cells of pG6(0119)DTAR with
1 promoter containing TAR [pG1(031)HIV LTR; Southgate pGAL4cTat2 or pGAL4Tat2(1–99) resulted in maximal
and Green, 1991]. With this promoter, Sp1 was brought transactivation, 281- and 270-fold, respectively (Fig. 3).
to the transcription complex through the heterologous Further deletion at the carboxy-terminus that removed
GAL4 DNA-binding site and Tat-2 was brought to the the basic region resulted in 194-fold transactivation or
transcription complex through TAR-1. Transactivation by 69% of wild-type activation function. The amino-terminal
Tat-2 in the presence of the GAL4-binding domain alone region can potentially form two a-helices (Echetebu and
Rice, 1993). Amino-terminal deletion to residue 18 thatwas 3.2-fold (Fig. 2). Transactivation by pGAL4-SP1WT
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function (Fig. 3). Thus, the lysine in the core region is
required for activation function for Tat-2.
Effects of mutations in Tat-2 were compared with a
target containing the HIV-2 LTR (pHIV2CAT) upstream of
the CAT reporter gene. As previously reported, removal
of the second exon resulted in slightly decreased trans-
activation of the HIV-2 LTR to 62% of wild type (Fig. 3).
Deletion of both the basic region and the second exon in
pGAL4TAT2(1–80) completely eliminated transactivation
function. Deletion of the first potential a-helix in pGAL4-
TAT2(18–130) resulted in 404-fold transactivation, but
deletion of both a-helices reduced transactivation to 26-
fold or 5% of wild-type function (Fig. 3). Deletion of the
internal potential a-helix also greatly reduced transacti-
vation to 8% of wild type. Point mutations in the basic
region and core region both eliminated transactivation
function (Fig. 3). Thus, transactivation of the HIV-2 LTR
requires residues 18 to 130 for optimal function. Because
residues 81 to 130 are not required for activation function,
these residues appear to provide RNA-binding function
in agreement with previously published work (Rhim and
Rice, 1993, 1994; Paktakhan and Tong-Starksen, 1995).
To determine the dependence of the activation domain
of Tat-2 on Sp1, we examined the activation function of
pGAL4cTAT2 in the absence and presence of binding
sites for Sp1 in synthetic promoters lacking TAR.
pG6(083)DTAR includes three binding sites for Sp1 and
a TATA box but nonfunctional TAR (Southgate and Green,FIG. 2. Tat-2 has greatest synergy with pGAL4-SP1WT. The target
1991). pG6(031)DTAR includes only the TATA box. Asplasmid, pG1(031)HIVLTR, contains one copy of the GAL4 DNA-re-
sponsive element (upstream activating sequence) upstream of a mini- shown in Fig. 4, pGAL4cTAT2, pGAL4TAT2(1–80), and
mal HIV-1 LTR (sequences 031 to /84) (Southgate and Green, 1991). pGAL4TAT2(R81–84A) all resulted in transactivation of
The effector plasmids express the indicated transcription factor fused the synthetic promoter containing Sp1-binding sites. In
to the GAL4-binding domain (residues 1–147) (Sadowski and Ptashne,
contrast, all three effector plasmids had minimal activity1989). Each effector plasmid was cotransfected with pG1(031)HIVLTR
with the target plasmid that lacked the binding sites forand filler DNA (pUC9) or pRSVTAT2. Basal activity was the CAT activity
resulting from pG1(031)HIVLTR in the presence of pUC9 alone and Sp1, pG6(031)DTAR (Fig. 4). As a negative control, the
was 0.31 { 0.03%. The graph shows the average fold transactivations effector plasmid containing a deletion of the amino-termi-
and SEM from at least three independent transfections. nus, pGAL4TAT2(46–130), did not transactivate either
synthetic promoter (Fig. 4).
removed one potential helix resulted in 76% of wild-type
activation function (Fig. 3). In contrast, removal of the Structural interactions between Sp1 and Tat-2
complete amino-terminal region to residue 45 in pGAL4-
TAT2(46–130) resulted in elimination of activation func- One potential mechanism for the functional synergy
between Sp1 and Tat-2 is that Sp1 helps to recruit Tat-tion (Fig. 3). Deletion of the internal potential helix in
residues 26 to 46 also completely reduced activation 2 to the transcription complex by binding to Tat-2. To
determine whether Tat-2 would bind to Sp1, GST–Tat-2function to 4.8-fold. Thus, the first 18 residues at the
amino-terminus and the 50 residues at the carboxy-termi- expressed in bacterial lysates was bound to glutathione –
Sepharose beads and incubated with HeLa whole-cellnus are not required for activation function. Residues 18
to 80 constitute the minimal activation domain for Tat-2. extracts. Bound proteins were separated by SDS–PAGE
and Western blots were performed to detect Sp1. AsPoint mutation of four arginine residues (R81–84) in
the basic region resulted in 208-fold activation or 74% of shown in Fig. 5A, Sp1 bound to wild-type GST–Tat-2
(lane 3). To determine the regions required for interac-wild-type function (Fig. 3). These results supported the
data from the carboxy-terminal deletion to residue 80 tions with Sp1, mutated Tat-2 that was fused to GST and
bound to beads was incubated with HeLa whole-cellin which R81–84 were not required for activation. As
observed in most lentiviral Tats, the core region of Tat- extracts. Western blot of the eluted proteins showed that
substitution mutations of the basic region eliminated in-2 contains a lysine (position 70) (Derse et al., 1991). Point
mutation of K70 in the core region eliminated activation teractions with Sp1 while deletion of the amino-terminal
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FIG. 3. Definition of the activation domain of Tat-2. A series of deletions and mutations of Tat-2 were fused to the GAL4 DNA-binding domain.
Plasmids expressing the indicated GAL4–Tat-2 fusion proteins downstream of the SV40 promoter were cotransfected with pHIV2CAT or the synthetic
target promoter, pG6(0119)DTAR, which contains six copies of UAS upstream of the HIV-1 LTR (sequences 0119 to /25) lacking TAR sequences
(Southgate and Green, 1991). 1 mg of target plasmid and 5 mg of effector plasmid were used in transfections with pG6(0119)DTAR. Basal activity
was the CAT activity in the presence of GAL4-binding domain alone (pSG424) and was 1.9 { 0.3% for pG6(0119)DTAR and 2.5 { 0.6% for pHIV2CAT.
Fold activation was determined as the ratio of CAT activity in the presence of the indicated GAL4–Tat-2 fusion divided by basal activity. Results
shown are the average fold transactivations from at least four independent transient transfections. SEM was less than 20% for each average.
region still resulted in binding (Fig. 5A, lanes 4 and 5). Domains in Sp1 required for functional synergy with
Tat-2Deletion of the basic region and of exon 2 in GST –
Tat2(1–80) resulted in loss of binding to Sp1 (Fig. 5A,
To further define the mechanism for functional synergylane 6). As a negative control, GST alone did not bind to
between Tat-2 and Sp1, we next identified the region(s)Sp1 (lane 2). All GST fusions were expressed well in
of Sp1 required for this synergy. Subdomains of Sp1 werebacterial lysates and used in equivalent amounts in bind-
fused to the GAL4-binding domain and cotransfecteding assays (Fig. 5B). Thus, GST–Tat-2 binds directly or
with the synthetic promoter, pG1(031)HIVLTR, whichindirectly to Sp1. However, this in vitro interaction local-
contains one copy of UAS upstream of the HIV-1 minimalizes to a different domain in Tat-2 than the in vivo func-
tional interactions. promoter including TAR (shown in Fig. 2; Southgate and
FIG. 4. Activation function of Tat-2 requires binding sites for Sp1. Plasmids expressing the indicated GAL4–Tat-2 fusion proteins downstream of
the SV40 promoter were cotransfected with the indicated synthetic promoter constructions. pG6(031)HIVDTAR and pG6(083)HIVDTAR contained
six copies of the UAS upstream of a minimal HIV-1 promoter that lacks TAR (positions 031 to/25 and positions 083 to/25, respectively) (Southgate
and Green, 1991). 1 mg of target plasmid and 5 mg of effector plasmid were used in each transfection. Basal activity shown for each promoter was
defined as the CAT activity in the presence of GAL4-binding domain alone. Fold activation was determined as the ratio of CAT activity in the
presence of the indicated GAL4 –Tat-2 fusion divided by basal activity. Results shown are the average fold transactivations and SEM from at least
four independent transient transfections.
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FIG. 5. In vitro binding between Tat-2 and Sp1 requires the basic residues in exon 1 of Tat-2. (A) GST alone (lane 2) or GST fused to wild-type
(lane 3) or mutated Tat-2 (lanes 4–6) was purified from E. coli lysates by binding to glutathione–Sepharose beads (Rhim et al., 1994). The amount
of GST or GST–Tat-2 protein used in incubation with HeLa WCE was about ninefold more than the amount shown in (B) at right. After washing,
proteins eluted from glutathione –Sepharose beads were run on 8% SDS–polyacrylamide gels, and Western blot for Sp1 was performed. Lane 1
contains 10 ml of HeLa WCE after incubation with bound GST alone. Protein molecular weight markers are shown in kilodaltons on the left. The
autoradiogram shown was representative of at least three reproducible experiments. (B) Purified fusion proteins from 1/10 of the bound GST–Tat-
2 used in (A) are shown after visualization with Coomassie blue staining.
Green, 1991). Sp1 contains two activation domains [re- in pGAL4SP1DBD(612–778) did not have any synergistic
effects with pRSVTAT2 or pRSVTAT1. The requirement forgions A (residues 83–262) and B (residues 263–542)]
and a DNA-binding domain that includes three zinc finger region A or B by Tat was also observed with a synthetic
promoter containing UAS, a minimal HIV-2 promoter, andmotifs (DBD, residues 612 –778) (Kadonaga et al., 1988).
pGAL4SP1A/B(83–621) had the greatest synergy with TAR-2 (data not shown). Thus, the activation domains of
Sp1, either A or B, contributed equally and additively topRSVTAT2, equivalent to that observed with full-length
Sp1 in pGAL4-SP1WT (compare Fig. 6 and Fig. 2). pGAL4- optimal function of Tat-2.
To further map the residues in region B that were re-SP1A and pGAL4SP1B also resulted in significant trans-
activation, 89- and 95-fold, respectively, with pRSVTAT2 quired for the function of Tat-2, we tested the amino-termi-
nal or carboxy-terminal portion of region B fused to the(Fig. 6). Similar synergies of regions A and B with Tat-1
were observed (Fig. 6). The DNA-binding region of Sp1 GAL4-binding domain in pGAL4SP1B-n(263–424) and
FIG. 6. Tat requires region A or B of Sp1 for functional synergy. The target plasmid was pG1(031)HIVLTR. The effector plasmids express the
indicated subdomains of Sp1 fused to GAL4 DNA-binding domain. Each effector plasmid (3 mg) was cotransfected with pG1(031)HIVLTR and
pRSVTAT1, pRSVTAT2, or filler DNA (pUC9). Basal activity of pG1(031)HIVLTR in the presence of pUC9 alone was 0.27 { 0.03% and normalized
to 1. Activation of pG(031)HIVLTR by pRSVTAT1 alone was 3.25-fold and by pRSVTAT2 alone was 3.22-fold. The graphs show the average fold
transactivations and SEM from at least four independent transfections.
AID VY 8847 / 6a53$$$243 10-24-97 22:43:03 vira AP: VY
228 PAGTAKHAN AND TONG-STARKSEN
7). In contrast, substitution mutations of three leucines
(L460,462,465) in pGAL4SP1(L–A) or three glutamines
(Q461,463,464) in pGAL4SP1(Q–A) resulted in wild-type
activities (Fig. 7). Effects of the glutamine and tryptophan
substitution mutations on functional synergy with Tat
were similar to effects with dTAFII110. The leucine substi-
tution mutations did not affect synergy with Tat, which is
in contrast to the lack of activity and binding of B-c with
dTAFII110 (Gill et al., 1994).
DISCUSSION
FIG. 7. Effects of point mutations in the carboxy-terminus of region B Tat-2 requires cellular coactivators to mediate effects
of Sp1. The target plasmid [pG5(031)HIVLTR] contains five copies of on the transcription complex. One coactivator is tran-
the GAL4 DNA-responsive element (UAS) upstream of the HIV-1 LTR scription factor Sp1. Functional dependence of Tat-2 on
(sequences 031 to /84) (Southgate and Green, 1991). The effector
Sp1 was demonstrated by the requirement for bindingplasmids express the GAL4 DNA-binding domain fused to wild-type
sites for Sp1 and by the requirement for Sp1 broughtresidues from the carboxy-terminus of region B of Sp1 (residues 421 to
542) or the indicated mutations (Gill et al., 1994). pG5(031)HIVLTR and to the promoter via a heterologous GAL4 system. To
each effector plasmid were cotransfected with pRSVTAT1, pRSVTAT2, understand the mechanisms for functional dependence
or filler DNA (pUC9). Basal activity was the CAT activity resulting from between Sp1 and Tat-2, we localized the activation do-
pG5(031)HIVLTR in the presence of pUC9 alone and was 0.22 { 0.3%.
main of Tat-2 to include one potential a-helix (residuesFold transactivation of pG5(031)HIVLTR over basal activation by each
18 to 46), the cysteine-rich region, and the core region.Tat-expressing plasmid and pGAL4SP1(425–542) was normalized to
100% and the fold activation by each mutation was expressed as a The independent activation function of Tat-2 required
percentage of wild-type activity. Activation of pG5(031)HIVLTR by binding sites for Sp1 when Tat-2 was brought to a mini-
pRSVTAT1 and pGAL4SP1(425 –542) was 313 { 45-fold. Activation of mal HIV-1 promoter via TAR or via a heterologous GAL4
pG5(031)HIVLTR by pRSVTAT2 and pGAL4SP1(425–542) was 312 {
system. In in vitro binding assays, we showed that Tat-264-fold.
bound to Sp1 but this binding localized to basic residues
outside of the activation domain. Mutational analysis of
Sp1 in the heterologous DNA-binding system showed
that either region A or B, each of which is an activationpGAL4SP1B-c(421–542), respectively (Gill et al., 1994).
Each GAL fusion was tested in the absence and presence domain of Sp1, was sufficient for functional interaction
with Tat-2 or Tat-1. Some mutations in region B in Sp1of pRSVTAT1 and pRSVTAT2 on the pG1(031)HIVLTR tar-
get. In the absence of any Tat, the carboxy-terminal portion that eliminate interactions with dTAFII110 also signifi-
cantly decreased activation by Tat. Thus, functional syn-of region B had 5.1-fold activation, which was similar to
the 6.1-fold activation observed with the entire region B ergy between Tat-2 and Sp1 correlates with interactions
between each activator and components of the general(Fig. 6). The amino-terminal portion of region B resulted in
only 1.4-fold activation (Fig. 6). pGAL4SP1B-c(421–542) transcription complex rather than with direct Tat-2/Sp1
binding.and pRSVTAT2 resulted in 36-fold transactivation while
pGAL4SP1B-n(263–424) and pRSVTAT2 resulted in 2-fold Structural and functional interactions between Tat-1 and
Sp1 have been demonstrated by several investigators.transactivation (Fig. 6). Similar relative effects were ob-
served with pRSVTAT1. Thus, transactivation by Tat was Functional dependence of Tat-1 for Sp1 is demonstrated
by the requirement for binding sites for Sp1 in transactiva-more dependent on the glutamine-rich, carboxy-terminal
portion than the serine–threonine-rich, amino-terminal por- tion of a minimal HIV-1 LTR (Jeang et al., 1993), and in-
creased spacing between these sites and the TATAA sitetion of region B.
Previous work has shown that one function of subdo- leads to a replication-defective viral genome (Huang and
Jeang, 1993). In addition, effects of Tat-1 in in vitro tran-main B-c is direct interaction with a component of TFIID,
dTAFII110 (Gill et al., 1994). Mutations that eliminate inter- scription systems require Sp1 (Sune and Garcia-Blanco,
1995; Zhou and Sharp, 1995). Recruitment of transcriptionaction with dTAFII110 also eliminate functional activity of
subdomain B-c in Drosophila cells. We tested the effects factors to a minimal HIV-1 promoter through the heterolo-
gous GAL4 system shows that greatest synergy with Tat-of mutations in subdomain B-c on transactivation by Tat
in transient cotransfections in HeLa cells. Substitution 1 is observed with Sp1 (region A) (Southgate and Green,
1991), although other transcription factors do supportmutations of residues 455 to 466, which alter a gluta-
mine-rich region within B-c, resulted in 31 and 18% of transactivation by Tat-1 (Southgate and Green, 1991; Ma-
dore and Cullen, 1995). We show that Tat-2 also results inwild-type activity for Tat-1 and Tat-2, respectively (Fig. 7).
Point mutation of W457A in pGAL4SP1(W–A) resulted in optimal transactivation with GAL4-SP1WT rather than
GAL4-E1a or GAL4-VP16 (Fig. 2).49 and 38% of wild-type activity for Tat-1 and Tat-2 (Fig.
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Binding of Tat-1 and Sp1 has been shown by retention and W457 while glutamines (Q461, Q463, Q464) are not
necessary (Gill et al., 1994). We find that mutation of W457of Sp1 from HeLa extracts in Tat-1 matrix columns (Jeang
et al., 1993) and GST – Tat-1 affinity columns (Sune and also results in decreased synergy with Tat-2. Mutations
of the leucines and glutamines have minimal effects onGarcia-Blanco, 1995). Direct in vitro binding is demon-
strated by cross-linking of purified Sp1 and Tat-1 (Jeang transactivation by Tat-2. Thus, some interactions of Sp1
with the human homologue of dTAFII110 may contributeet al., 1993) and by binding of GST–Tat-1 with recombi-
nant purified Sp1 (Sune and Garcia-Blanco, 1995). In vivo to functional synergy with Tat-2 but interactions between
this TAF and Sp1 are not essential for synergy with Tat-association is suggested by coimmunoprecipitation of
Tat-1 and Sp1 in cells infected with HIV-1 (Jeang et al., 2. Sp1 binds to other TAFs (Chiang and Roeder, 1995) and
hTBP (Emili et al., 1994), and these interactions may be1993). Localization of the region of Tat-1 required for
binding with Sp1 shows that residues 30 to 62, which required for synergy with Tat-2.
Our data are consistent with previous observationsinclude the cysteine-rich, core, and basic region, are suf-
ficient (Jeang et al., 1993), while the lysine in the core that Sp1 binds to components of TFIID (Emili et al., 1994;
Gill et al., 1994) and mediates increased transcriptionregion (L41A) is not required for binding (Sune and Gar-
cia-Blanco, 1995). Thus, our GST binding assays that initiation through these interactions (Blau et al., 1996). We
would hypothesize that the presence of Sp1 and TFIIDshow a requirement for the basic residues in exon 1 of
Tat-2 are consistent with the binding data for Tat-1 and at the promoter allows Tat to convert the transcription
complex into a processive form. In our system, we wereSp1. Although our data do not distinguish between direct
or indirect Tat-2/Sp1 binding, studies on Tat-1 would sug- not able to detect binding of Tat-2 to TBP but do detect
binding of Tat-2 to the elongation factor TFIIH in thegest direct binding. Our observation that the amino-termi-
nus of Tat-2 is not necessary for binding to Sp1 indicates, holoenzyme complex (data not shown). Sp1/TFIID inter-
actions could result in recruitment of and conformationalhowever, that direct interactions are not the primary
mechanism for the in vivo functional synergy of these changes in the holoenzyme complex bound to Tat as
well as phosphorylation of transcription factors. In thetransactivators with the HIV promoter. It is possible that
the direct interactions contribute to the function of Tat absence of Sp1, binding of TFIID to the TATA box may
be unstable and subsequent interactions with the holo-with promoters lacking TAR sequences. For example, Tat
1 represses the MHC class I promoter and this effect enzyme complex would not occur. Further studies on
sequential recruitment of factors in in vitro transcriptionrequires Sp1-like cis-elements (Howcroft et al., 1995).
Our data confirm and extend previous work in which systems, activator bypass experiments, and studies on
Sp1/Tat interactions in TAR-independent promoters willthe activation function of Tat-2 is observed with residues
1 to 77 but not with an internal deletion of residues 8 to confirm this model system.
33 or 8 to 47 (Rhim and Rice, 1994). We demonstrate that
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